Cargando…
Efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol
INTRODUCTION: Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed and treated childhood psychiatric disorders. The analogous diagnosis adopted in Europe is hyperkinetic disorder, which is defined in the WHO’s International Classification of Diseases 10th edition (IC...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855296/ https://www.ncbi.nlm.nih.gov/pubmed/29463592 http://dx.doi.org/10.1136/bmjopen-2017-020434 |
_version_ | 1783307070614798336 |
---|---|
author | He, Sufei Wang, Miao Si, Jinhua Zhang, Tianyi Cui, Hong Gao, Xiumei |
author_facet | He, Sufei Wang, Miao Si, Jinhua Zhang, Tianyi Cui, Hong Gao, Xiumei |
author_sort | He, Sufei |
collection | PubMed |
description | INTRODUCTION: Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed and treated childhood psychiatric disorders. The analogous diagnosis adopted in Europe is hyperkinetic disorder, which is defined in the WHO’s International Classification of Diseases 10th edition (ICD-10). Hyperkinetic disorder includes more severe conditions. Ginkgo preparations are used in the treatment of ADHD. The present study will assess the efficacy and safety of ginkgo preparations in the treatment of ADHD in the currently published literature. MATERIALS AND METHODS: All prospective randomised controlled trials (RCTs) will be included in this systematic review. Patients diagnosed with ADHD according to American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders fourth edition (DSM-IV), Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), ICD-10 or Chinese Classification and Diagnosis of Mental Diseases third edition (CMDD) will be included. A comprehensive search for RCTs to evaluate the effectiveness and tolerance of ginkgo preparations will be performed. The primary outcomes are the ADHD Rating Scale-IV and Revised Conners’ Parent Rating Scale. The secondary outcomes are quality of life evaluated by the KINDL scale, adverse effects/events, Conners’ Teacher Rating Scale, Strengths and Weaknesses of ADHD Symptoms and Normal Behaviour Scale and Fremdbeurteilungsbogen für Hyperkinetische Störungen. Exclusion criteria are the following: (1) case reports, not randomised trial, non-comparative studies and (2) patients who were not diagnosed based on DSM-IV, DSM-5, ICD-10 or CMDD. The following databases will be searched from their inception until January 2018: Medline, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, China Biology Medicine Disc, China National Knowledge Infrastructure Database, Wanfang Database and Chinese Scientific Journals Database. Two authors will independently perform the study selection, extract the data and assess the study quality and risk of bias. ETHICS AND DISSEMINATION: This systematic review does not require ethics approval. It will be published in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42017077190. |
format | Online Article Text |
id | pubmed-5855296 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-58552962018-03-19 Efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol He, Sufei Wang, Miao Si, Jinhua Zhang, Tianyi Cui, Hong Gao, Xiumei BMJ Open Complementary Medicine INTRODUCTION: Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed and treated childhood psychiatric disorders. The analogous diagnosis adopted in Europe is hyperkinetic disorder, which is defined in the WHO’s International Classification of Diseases 10th edition (ICD-10). Hyperkinetic disorder includes more severe conditions. Ginkgo preparations are used in the treatment of ADHD. The present study will assess the efficacy and safety of ginkgo preparations in the treatment of ADHD in the currently published literature. MATERIALS AND METHODS: All prospective randomised controlled trials (RCTs) will be included in this systematic review. Patients diagnosed with ADHD according to American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders fourth edition (DSM-IV), Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), ICD-10 or Chinese Classification and Diagnosis of Mental Diseases third edition (CMDD) will be included. A comprehensive search for RCTs to evaluate the effectiveness and tolerance of ginkgo preparations will be performed. The primary outcomes are the ADHD Rating Scale-IV and Revised Conners’ Parent Rating Scale. The secondary outcomes are quality of life evaluated by the KINDL scale, adverse effects/events, Conners’ Teacher Rating Scale, Strengths and Weaknesses of ADHD Symptoms and Normal Behaviour Scale and Fremdbeurteilungsbogen für Hyperkinetische Störungen. Exclusion criteria are the following: (1) case reports, not randomised trial, non-comparative studies and (2) patients who were not diagnosed based on DSM-IV, DSM-5, ICD-10 or CMDD. The following databases will be searched from their inception until January 2018: Medline, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, China Biology Medicine Disc, China National Knowledge Infrastructure Database, Wanfang Database and Chinese Scientific Journals Database. Two authors will independently perform the study selection, extract the data and assess the study quality and risk of bias. ETHICS AND DISSEMINATION: This systematic review does not require ethics approval. It will be published in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42017077190. BMJ Publishing Group 2018-02-20 /pmc/articles/PMC5855296/ /pubmed/29463592 http://dx.doi.org/10.1136/bmjopen-2017-020434 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Complementary Medicine He, Sufei Wang, Miao Si, Jinhua Zhang, Tianyi Cui, Hong Gao, Xiumei Efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol |
title | Efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol |
title_full | Efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol |
title_fullStr | Efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol |
title_full_unstemmed | Efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol |
title_short | Efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol |
title_sort | efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol |
topic | Complementary Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855296/ https://www.ncbi.nlm.nih.gov/pubmed/29463592 http://dx.doi.org/10.1136/bmjopen-2017-020434 |
work_keys_str_mv | AT hesufei efficacyandsafetyofginkgopreparationsforattentiondeficithyperactivitydisorderasystematicreviewprotocol AT wangmiao efficacyandsafetyofginkgopreparationsforattentiondeficithyperactivitydisorderasystematicreviewprotocol AT sijinhua efficacyandsafetyofginkgopreparationsforattentiondeficithyperactivitydisorderasystematicreviewprotocol AT zhangtianyi efficacyandsafetyofginkgopreparationsforattentiondeficithyperactivitydisorderasystematicreviewprotocol AT cuihong efficacyandsafetyofginkgopreparationsforattentiondeficithyperactivitydisorderasystematicreviewprotocol AT gaoxiumei efficacyandsafetyofginkgopreparationsforattentiondeficithyperactivitydisorderasystematicreviewprotocol |